27 Jan 2021 --- Sabinsa’s Curcumin C3 Reduct ingredient has potential in oral care applications, according to a new clinical trial. The findings build on previous research and show beneficial outcomes for mouth and gum-related diseases.“Discovering herbal-based treatments in conditions where no satisfactory pharma therapy is readily available continues to drive our innovation,” says Dr. Muhammed Majeed, founder and chairman of the Sami-Sabinsa Group.